about
The role of protein C inhibitor in human reproductionInsights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targetsGenome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysmHeart failure induces significant changes in nuclear pore complex of human cardiomyocytes.Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis.Differential gene expression of cardiac ion channels in human dilated cardiomyopathy.Spanish Consensus Statement: The Treatment of Muscle Tears in Sport.Fibrinolysis: the key to new pathogenetic mechanisms.The endothelial cell protein C receptor: its role in thrombosis.Role of microRNAs in gynecological pathology.Limited ability to activate protein C confers left atrial endocardium a thrombogenic phenotype: a role in cardioembolic stroke?microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer.Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect.Dyslipidaemia in Behcet's disease as a thrombotic risk factor.Comparison of protocols and RNA carriers for plasma miRNA isolation. Unraveling RNA carrier influence on miRNA isolation.Assessment of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma.Spanish Consensus Statement: Clinical Management and Treatment of Tendinopathies in Sport.Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.Activated protein C levels in obesity and weight loss influence.Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.Erythrocyte hyperaggregation in obesity: determining factors and weight loss influence.Characterization of variants in the glucosylceramide synthase gene and their association with type 1 Gaucher disease severity.α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.Red blood cell distribution width in patients with cryptogenic stroke.MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors.microRNAs expression in endometriosis and their relation to angiogenic factors.A simplified assay for the quantification of circulating activated protein C.mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.Elevated serum amyloid A is associated with venous thromboembolism.Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases.Heritability of plasma concentrations of activated protein C in a Spanish populationInfluence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosisFibrinogen, plasma viscosity and blood viscosity in obesity. Relationship with insulin resistanceThe role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancerExpression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosisThrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C systemExpression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancerCirculating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesionsActivated protein C levels in Behçet's disease and risk of venous thrombosisEffect of carazolol on the oestrous behaviour and concentrations of luteinising hormone and steroids in lactating cows during the periovulatory period
P50
Q28285047-3F3DC8A1-6520-44B8-AF03-9FD564348764Q28306940-249C485D-2DE4-4B4C-9004-CD359BC770CBQ28943557-308DD357-680F-4683-8F53-6A150CF23FB1Q34477603-7C99AB7A-937B-44DB-A97F-76D0A1A002D8Q34689624-1AA8577F-84EF-451D-8A1F-A9489EEA4992Q35067294-DC3F0BE6-4754-4E9E-B729-ED1DEA6F3318Q36455038-0A4F0446-D098-4B9D-94DF-D6C7DD354BFEQ37160777-114654E2-94E9-4C07-9AEE-59FE8000C9E7Q37929369-BF22ED22-1E43-4F08-930E-5225FC31866AQ37997854-6B7BD4C8-843C-4C06-853C-6412286C0CC9Q38543460-3ACCBDF5-C566-4215-B46E-FC6D707383CAQ39567135-165F1505-EE7A-4C5A-9BC3-D4809D62E025Q39743484-A931476E-201B-4EB8-A057-22CE65789009Q42955649-24B519BE-D72D-4B50-9065-B25A53F2238EQ43412551-57083BC3-E5A7-4F08-BA08-DB845A130E2EQ45883307-53540826-B356-43AD-8120-C8B19C437549Q46414685-74B3CEE0-E0C3-482F-9FBF-61B09B1CE554Q46701476-3B36391C-AA29-49DA-A4DD-84728A061E51Q47213111-DD25F186-3802-4669-AAB2-FB9106DAB3A7Q47259968-B35F3125-A763-457A-B5BC-E03EEA5BFD4FQ47273555-F7E90F58-85F9-46CF-B84B-D647269C7486Q47862820-C3F5746D-D7E5-4BD0-AE65-67F64D827071Q49966935-6998905F-D05A-468A-AC26-FC1C4CC1C386Q50461848-A7BF72B9-CDA9-4ADD-9B23-B911477A2BBAQ50477507-249990D2-EF8F-40A9-9FC7-8A62A02D246DQ50526432-19CDE8FF-C46C-4A60-8F7C-4B8A89FED0A7Q51719824-51FC40E6-0614-401D-994C-40986E91E0ACQ54690794-851DFA26-C4E0-4274-A095-C921E7167B41Q55431345-7EA4A003-AB37-48B1-A467-47E36AB67B4FQ55652795-643218F8-6814-4E1B-A030-35850DA683E6Q59590819-C94336F6-B20F-4A10-989A-E878D5695F63Q63503844-2D36259D-5C9D-49FA-8115-FF7D52F14993Q63503884-912D330E-43D1-44A4-859C-D011E171D646Q73437865-A5B1F8D8-088A-4445-AC27-8F33CAD146BBQ73587428-4586BF44-D5BB-45FC-92C0-CF11EFAEC739Q73903671-E56F8BD3-2F56-44E4-BBA7-264BD32C3682Q79676677-742A2075-4CFB-4955-8369-C5EBE431D535Q79898672-92E6872C-76DF-4515-8B53-9CEDFFBF32F6Q80405763-95E9ADD8-C562-4638-B5AA-765AA2F84356Q80451700-DC756E40-4EC3-4A5E-8ED4-CB92234189AF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francisco España
@ast
Francisco España
@en
Francisco España
@es
Francisco España
@nl
type
label
Francisco España
@ast
Francisco España
@en
Francisco España
@es
Francisco España
@nl
prefLabel
Francisco España
@ast
Francisco España
@en
Francisco España
@es
Francisco España
@nl
P106
P21
P31
P496
0000-0001-7829-2021